Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.

Maunoury, Franck

Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France. [electronic resource] - PloS one 2018 - e0194329 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1932-6203

10.1371/journal.pone.0194329 doi


Amides
Antiviral Agents--economics
Benzofurans--economics
Carbamates
Cost-Benefit Analysis--methods
Cyclopropanes
Drug Therapy, Combination--economics
Female
France
Genotype
Hepacivirus--genetics
Hepatitis C, Chronic--complications
Humans
Imidazoles--economics
Kidney Failure, Chronic--complications
Liver Cirrhosis--complications
Male
Middle Aged
Models, Economic
Quality-Adjusted Life Years
Quinoxalines--economics
RNA, Viral--genetics
Randomized Controlled Trials as Topic
Renal Dialysis
Sulfonamides